BioSpace News Archive

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced data updates from two phase 1/2a trials with AFM24, the company’s tetravalent, bispecific innate cell engager, in patients with solid tumors.

Amarin Corporation plc highlighted key data presented at the American Heart Association 2022 Scientific Sessions relevant to VASCEPA®/VAZKEPA and patient care.

ReWalk Robotics Ltd., a leading manufacturer of robotic medical technology for people with lower extremity disabilities, announced its financial results for the three and nine months ended September 30, 2022.

Intercept Pharmaceuticals, Inc. announced additional supportive data from its pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to nonalcoholic steatohepatitis.

Shattuck Labs, Inc. announced preclinical data from the company’s novel GADLEN platform at the 2022 SITC Annual Meeting.

Inhibikase Therapeutics, Inc. announced that the Company was informed via e-mail communication that the U.S. FDA has reviewed its Investigational New Drug application for IkT-148009 for the treatment of Multiple Systems Atrophy and has issued a Clinical Hold on the IkT-148009 201 program in Parkinson’s disease and the use of IkT-148009 in MSA.

SeekIn Inc announced the results of the pan-cancer/pan-indication treatment response monitoring test, SeekInClarity®, which were presented at the AMP 2022 Annual Meeting & Expo in Phoenix, Arizona, United States.

Renibus Therapeutics, Inc., (“Renibus”) today announced that interim Phase 2 data for RBT-1 (stannous protoporphyrin/iron sucrose) were presented during an oral session at the American Heart Association (AHA) Scientific Sessions 2022 meeting, being held November 5-7, 2022, in Chicago, Illinois.

OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has developed a novel predictive model for clinical benefit of immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients.

Actym Therapeutics announced today that an abstract highlighting detailed in vivo and in vitro preclinical data of its lead candidate, ACTM-838, was accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022.